2-(4-methylbenzyl)-4-(4-chlorobenzyl)-1,2,4-thiadiazolidine-3,5-dione | 1352552-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methylbenzyl)-4-(4-chlorobenzyl)-1,2,4-thiadiazolidine-3,5-dione
• 英文别名: 4-[(4-Chlorophenyl)methyl]-2-[(4-methylphenyl)methyl]-1,2,4-thiadiazolidine-3,5-dione；4-[(4-chlorophenyl)methyl]-2-[(4-methylphenyl)methyl]-1,2,4-thiadiazolidine-3,5-dione
• CAS: 1352552-29-4
• 化学式: C₁₇H₁₅ClN₂O₂S
• 分子量: 346.837
• InChiKey: SLTWNUACEGNWDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  65.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯苄基硫代异氰酸酯 、 4-甲基苄基异氰酸酯 在 磺酰氯 、 氧气 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 以69%的产率得到2-(4-methylbenzyl)-4-(4-chlorobenzyl)-1,2,4-thiadiazolidine-3,5-dione
  参考文献：
  名称：

  Small Molecule Inhibitors of Regulators of G Protein Signaling (RGS) Proteins

  摘要：

  Recently, regulators of G protein signaling (RGS) proteins have emerged as potential therapeutic targets since they provide an alternative method of modulating the activity of G protein-coupled receptors, the target of so many drugs. Inhibitors of RGS proteins must block a protein protein interaction (RGS-G alpha) but also be cell and, depending on the therapeutic target, blood brain barrier permeable. A lead compound (la) was identified as an inhibitor of RGS4 in a screening assay, and this has now been optimized for activity, selectivity, and solubility. The newly developed ligands (11b and 13) display substantial selectivity over the closely related RGS8 protein, lack the off-target calcium mobilization activity of the lead la, and have excellent aqueous solubility. They are currently being evaluated in vivo in rodent models of depression.

  DOI：

  10.1021/ml200263y

文献信息

• SMALL MOLECULE INHIBITORS OF RGS PROTEINS
  申请人：Neubig Richard

  公开号：US20120277273A1

  公开（公告）日：2012-11-01

  The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).

  该发明涉及具有RGS（G蛋白信号调节因子）抑制活性的组合物，以及其使用方法。在某些实施例中，具有RGS抑制活性的组合物可用于研究或治疗疾病状态（例如糖尿病、癫痫、神经痛、抑郁症和其他疾病）。
• MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS
  申请人：Otonomy, Inc.

  公开号：EP3508197A1

  公开（公告）日：2019-07-10

  Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s).

  本文公开了调节含聚氧乙烯酰胺制剂凝胶温度的方法。本文还描述了持续释放药物制剂，这些制剂与人体接触后会凝胶化，可通过将这些组合物和制剂直接涂抹在目标结构上或灌注到目标结构中进行给药。
• Modulation of Gel Temperature of Poloxamer-Containing Formulations
  申请人：Ye Qiang

  公开号：US20120277199A1

  公开（公告）日：2012-11-01

  Disclosed herein are methods for modulation of gel temperature of poloxamer-containing formulations. Also described herein are sustained release pharmaceutical formulations that gel upon contact with the body and are administered by direct application of these compositions and formulations onto or via perfusion into the targeted structure(s).
• Prevention of and Recovery from Drug-Induced Ototoxicity
  申请人：Piu Fabrice

  公开号：US20130045957A1

  公开（公告）日：2013-02-21

  Provided herein are methods for preventing and/or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.
• PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY
  申请人：Otonomy, Inc.

  公开号：US20180036231A1

  公开（公告）日：2018-02-08

  Provided herein are methods for preventing and/or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.